全文获取类型
收费全文 | 123028篇 |
免费 | 6476篇 |
国内免费 | 169篇 |
专业分类
耳鼻咽喉 | 1846篇 |
儿科学 | 5473篇 |
妇产科学 | 4088篇 |
基础医学 | 16724篇 |
口腔科学 | 3006篇 |
临床医学 | 8863篇 |
内科学 | 23569篇 |
皮肤病学 | 3527篇 |
神经病学 | 9459篇 |
特种医学 | 5227篇 |
外国民族医学 | 32篇 |
外科学 | 20545篇 |
综合类 | 1711篇 |
一般理论 | 31篇 |
预防医学 | 6068篇 |
眼科学 | 3608篇 |
药学 | 8650篇 |
中国医学 | 357篇 |
肿瘤学 | 6889篇 |
出版年
2021年 | 908篇 |
2019年 | 876篇 |
2018年 | 1244篇 |
2017年 | 1003篇 |
2016年 | 1371篇 |
2015年 | 1471篇 |
2014年 | 2001篇 |
2013年 | 2805篇 |
2012年 | 3813篇 |
2011年 | 3823篇 |
2010年 | 2350篇 |
2009年 | 2275篇 |
2008年 | 3657篇 |
2007年 | 3918篇 |
2006年 | 3994篇 |
2005年 | 4054篇 |
2004年 | 3915篇 |
2003年 | 3735篇 |
2002年 | 3644篇 |
2001年 | 7047篇 |
2000年 | 6993篇 |
1999年 | 5890篇 |
1998年 | 1647篇 |
1997年 | 1583篇 |
1996年 | 1355篇 |
1995年 | 1217篇 |
1994年 | 1104篇 |
1993年 | 1133篇 |
1992年 | 3803篇 |
1991年 | 3605篇 |
1990年 | 3578篇 |
1989年 | 3364篇 |
1988年 | 2999篇 |
1987年 | 2914篇 |
1986年 | 2818篇 |
1985年 | 2639篇 |
1984年 | 1954篇 |
1983年 | 1603篇 |
1982年 | 932篇 |
1981年 | 923篇 |
1979年 | 1831篇 |
1978年 | 1350篇 |
1977年 | 1121篇 |
1976年 | 940篇 |
1975年 | 1181篇 |
1974年 | 1215篇 |
1973年 | 1200篇 |
1972年 | 1041篇 |
1971年 | 976篇 |
1970年 | 881篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Martin R. Späth Malte P. Bartram Nicolàs Palacio-Escat K. Johanna R. Hoyer Cedric Debes Fatih Demir Christina B. Schroeter Amrei M. Mandel Franziska Grundmann Giuliano Ciarimboli Andreas Beyer Jayachandran N. Kizhakkedathu Susanne Brodesser Heike Göbel Jan U. Becker Thomas Benzing Bernhard Schermer Martin Höhne Markus M. Rinschen 《Kidney international》2019,95(2):333-349
3.
Sajid Amit Lumbini Barua Abdulla - Al Kafy 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(4):102129
Background and aimsWorldwide the COVID-19 pandemic has accelerated sufferings of mental health and behaviour attitudes of people. Many countries, including Bangladesh, reported suicide as extreme consequences of the psychological burden influenced by COVID-19. The present study explores human stress and its factor influenced by COVID-19 in Bangladesh, which significantly affect the quality of life.MethodsAn online-based questionnaire survey was conducted among 651 adult Bangladeshi populations by capturing socio-demographic information, possible human stress, and consequences of the pandemic. A set of statistical tools such as Pearson's Correlation Matrix (PCM), T-test, Principal Component Analysis (PCA) and Hierarchical Cluster Analysis (HCA) were applied to identify the relationship between different factors and influential factors increasing human stress.ResultsMore than 83% of the participants are facing COVID-19 related mental stress, which results in short temper, sleep disorder, and family chaos. PCA and HCA outcomes indicated a significant relationship between the respondents' opinions and human stress factors, which harmonized with the country's existing scenario. PCM results enlighten the relationship between human stress factors and found financial hardship, cutting back daily spending, and food crisis are interconnected together causes stress. Also, hampering students' formal education and future career plans significantly contribute to mental stress.ConclusionBased on the above findings, it's crucial to introduce a time-oriented strategy and implement precaution monitoring plans for Bangladesh. The rescue plan will help people to manage the pandemic and improve mental health to fight against psychological challenges related to COVID-19 and future pandemics. 相似文献
4.
5.
Usha Patel Manish Pandey Sadhana Kannan Tanuja A. Samant Poonam Gera Neha Mittal Swapnil Rane Asawari Patil Vanita Noronha Amit Joshi Vijay M. Patil Kumar Prabhash Manoj B. Mahimkar 《British journal of cancer》2020,123(12):1757
Background Anti-EGFR-based therapies have limited success in HNSCC patients. Predictive biomarkers are greatly needed to identify the patients likely to be benefited from these targeted therapies. Here, we present the prognostic and predictive association of biomarkers in HPV-negative locally advanced (LA) HNSCC patients.Methods Treatment-naive tumour tissue samples of 404 patients, a subset of randomised Phase 3 trial comparing cisplatin radiation (CRT) versus nimotuzumab plus cisplatin radiation (NCRT) were analysed to evaluate the expression of HIF1α, EGFR and pEGFR by immunohistochemistry and EGFR gene copy change by FISH. Progression-free survival (PFS), locoregional control (LRC) and overall survival (OS) were estimated by Kaplan–Meier method. Hazard ratios were estimated by Cox proportional hazard models.Results Baseline characteristics of the patients were balanced between two treatment groups (CRT vs NCRT) and were representative of the trial cohort. The median follow-up was of 39.13 months. Low HIF1α was associated with better PFS [HR (95% CI) = 0.62 (0.42–0.93)], LRC [HR (95% CI) = 0.56 (0.37–0.86)] and OS [HR (95% CI) = 0.63 (0.43–0.93)] in the CRT group. Multivariable analysis revealed HIF1α as an independent negative prognostic biomarker. For patients with high HIF1α, NCRT significantly improved the outcomes [PFS:HR (95% CI) = 0.55 (0.37–0.82), LRC:HR (95% CI) = 0.55 (0.36–0.85) and OS:HR (95% CI) = 0.54 (0.36–0.81)] compared to CRT. While in patients with low HIF1α, no difference in the clinical outcomes was observed between treatments. Interaction test suggested a predictive value of HIF1α for OS (P = 0.008).Conclusions High HIF1α expression is a predictor of poor clinical response to CRT in HPV-negative LA-HNSCC patients. These patients with high HIF1α significantly benefited with the addition of nimotuzumab to CRT.Clinical trial registration Registered with the Clinical Trial Registry of India (Trial registration identifier—CTRI/2014/09/004980).Subject terms: Tumour biomarkers, Head and neck cancer, Tumour biomarkers, Head and neck cancer, Predictive markers 相似文献
6.
7.
Richard Kim Elaine Tan Emily Wang Amit Mahipal Dung-Tsa Chen Biwei Cao Fadzai Masawi Cindy Machado James Yu Dae Won Kim 《The oncologist》2020,25(12):e1893-e1899
Lessons Learned
- The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy.
- Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily.
- The limited anticancer activity observed in this unselected patient population does not support further exploration of trametinib plus sorafenib in patients with hepatocellular carcinoma.
8.
9.
10.